E

Looking east at a now familiar horizon

A careful look at what we can learn from the Beigene anti-TIGIT data for ociperlimab

July 6, 2021
E

Tackling immunosuppression with a dual approach to TIGIT and adenosine

Do we need to target the adenosine fog as well as TIGIT in NSCLC?

June 24, 2021
E

A twist in the IO tail

Going beyond the obvious conclusion with anti-LAG3 therapy

May 19, 2021
E

Emerging developments and trends in advanced lung cancer

Gems from the WCLC20 poster hall which may make an impact

February 9, 2021
E

Parallel lines: opportunities and challenges in GI cancers

Important developments on the GI cancer front to watch out for

January 19, 2021
E

A contrarian view of key cancer trial results

Winners, losers and risers... who goes where in the final analysis?

October 8, 2020
E
Hubble Space Telescope, Spitzer Space Telescope

On black holes and rising supernova stars in oncology

Rising stars become supernovas or disappear into a black hole of R&D - a look at what we can learn from one company's early stage compounds

October 6, 2020
E

Can we add fire to the immune system with TIGIT?

A look at Genentech's tiragolumab (anti-TIGIT) in advanced lung cancer

June 1, 2020
E

Putting some colour on the TIGIT niche

A look at what a young up and coming biotech in the TIGIT space are doing and how they see their approach being differentiated from the competition.

May 12, 2020
E

Every cloud has a silver lining

What to watch out for at AACR20 - the first of our meeting previews is here!

April 15, 2020
E

10 early phase ASH19 abstracts with a difference

A look at off Broadway abstracts on early new product development and scientific findings of interest

November 26, 2019
E

Next generation approaches to immuno-oncology – where next?

What's next in immuno-oncology: what are potential ways to tackle the patients who do not respond to checkpoint immunotherapy?

January 8, 2015